Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. [electronic resource]
Producer: 20190208Description: e0202777 p. digitalISSN:- 1932-6203
- 2-Naphthylamine
- Aged
- Aged, 80 and over
- Anilides -- administration & dosage
- Antiviral Agents -- administration & dosage
- Carbamates -- administration & dosage
- Cohort Studies
- Cyclopropanes
- Drug Therapy, Combination
- Female
- Genotype
- Hepacivirus -- genetics
- Hepatitis C, Chronic -- drug therapy
- Humans
- Hyperbilirubinemia -- chemically induced
- Lactams, Macrocyclic
- Liver Cirrhosis -- drug therapy
- Macrocyclic Compounds -- administration & dosage
- Male
- Middle Aged
- Proline -- analogs & derivatives
- Prospective Studies
- Risk Factors
- Ritonavir -- administration & dosage
- Sulfonamides -- administration & dosage
- Sustained Virologic Response
- Treatment Outcome
- Uracil -- administration & dosage
- Valine
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.